GlassScriptPhysician profile
Heather J Hitt
NPI 1417603069
$3,220.61
in general payments reported to CMS, 2019-2025
28 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.58 · 2023: $1,702 · 2024: $1,170 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,109 · Education: $96.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.58 |
| Education | $96.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $496.48 | 2023-2024 | Lokelma, Farxiga |
| Mallinckrodt Hospital Products INC. | $390.04 | 2023-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $324.65 | 2023-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $290.92 | 2023-2024 | Jynarque |
| Calliditas Therapeutics US INC. | $266.42 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $170.49 | 2023-2024 | |
| Horizon Therapeutics Plc | $146.28 | 2023 | Krystexxa |
| Amgen INC. | $143.69 | 2024 | Krystexxa |
| Travere Therapeutics, INC. | $133.37 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $126.79 | 2023-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $115.52 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.25 | 2023-2024 | Jardiance |
| Lilly USA, LLC | $68.49 | 2023-2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $54.63 | 2023-2025 | Lupkynis |
| Ardelyx, INC. | $51.37 | 2024-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $49.86 | 2024 | |
| Glaxosmithkline, LLC. | $49.06 | 2023-2025 | Arexvy, Shingrix, Benlysta |
| Alexion Pharmaceuticals, INC. | $38.09 | 2023-2024 | Ultomiris |
| Averitas Pharma INC. | $31.55 | 2024 | Qutenza |
| Kyowa Kirin, INC. | $29.66 | 2024 | Crysvita |
| Akebia Therapeutics INC | $26.13 | 2024 | Vafseo, Auryxia |
| Takeda Pharmaceuticals U.S.A., INC. | $24.22 | 2023 | Gattex |
| Alnylam Pharmaceuticals INC. | $23.92 | 2025 | Givlaari |
| Fresenius USA Marketing, INC. | $23.39 | 2024 | Velphoro |
| Opko Pharmaceuticals, LLC | $22.46 | 2023 | Rayaldee |
| Ultragenyx Pharmaceutical INC. | $17.54 | 2023 | |
| Apellis Pharmaceuticals, INC. | $16.00 | 2025 | Empaveli |
| Viiv Healthcare Company | $14.34 | 2023 | Rukobia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Hitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.